

PANRETIN (alitretinoin 0.1% gel)

Effective Date: 1/28/14

Date Developed: 1/28/14 by Robert Sterling, MD

Last Approval Date: 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20

Panretin is a naturally-occurring retinoid related to vitamin A that activates processes which regulate cell differentiation and proliferation. It has been shown to inhibit the growth of Kaposi's sarcoma cells in vitro.

Authorization: for topical treatment of cutaneous Kaposi's sarcoma lesions who do not qualify for systemic treatment (e.g. no visceral/pulmonary involvement; no >10 new cutaneous lesions in the past month), for treatment of severe chronic hand eczema refractory to topical corticosteroids.

Dosing: apply two times a day, gradually increasing to four times a day if necessary; avoid normal skin

PRECAUTIONS: photosensitivity; irritation to normal skin; extreme reaction of the lesions (pain, exfoliation, paresthesias)

DRUG INTERACTIONS: concomitant use of DEET-containing preparations

REFERENCES

Walmsley S, Northfelt DW, Melosky B, et al. Treatment of AIDS-related cutaneous kaposi sarcoma with topical alitretinoin (9-cis-retinoic acid) J Acquir Immune Defic Syndr. 1999;22(3):235–246.

Duvic M, Friedman-Kien AE, Looney DJ, et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related kaposi sarcoma using alitretinoin gel. Results of phase 1 and 2 trials. Arch Dermatol. 2000;136(12):1461–1469.

Miles SA, Dezube BJ, Lee JY, et al. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated kaposi's sarcoma. AIDS. 2002;16(3):421–429.

Bodsworth NJ, Bloch M, Bower M, Donnell D, Yocum R. for The International Panretin® Gel KS study group. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related kaposi's sarcoma. Am J Clin Dermatol. 2001;2(2):77–87.

Cheng C, Michaels J, Scheinfeld N. Alitretinoin: a comprehensive review. Expert Opin Investig Drugs. 2008;17(3):437–443.

Revision History:

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD

Date Approved by P&T Committee: 1/27/15

Date Reviewed/No Updates: 1/26/16 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/26/16

Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/24/17

Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/23/18

Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD

Date Approved by P&T Committee: 1/22/19

Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD

Date Approved by P&T Committee: 2/18/20

Revision Date	Content Revised (Yes/No)	Contributors	Review/Revision Notes
1/24/17	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/23/18	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
1/22/19	No	Catherine Sanders, MD; Robert Sterling, MD	Annual review
2/18/20	No	Howard Taekman, MD; Robert Sterling, MD	Annual review